Urteste S.A. (WSE:URT)

Poland flag Poland · Delayed Price · Currency is PLN
54.60
-0.40 (-0.73%)
Jun 6, 2025, 4:19 PM CET
-41.29%
Market Cap 74.71M
Revenue (ttm) 1.54M
Net Income (ttm) -3.04M
Shares Out 1.41M
EPS (ttm) -2.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 249
Average Volume 470
Open 58.00
Previous Close 55.00
Day's Range 52.40 - 58.00
52-Week Range 52.40 - 107.00
Beta 0.06
RSI 23.56
Earnings Date Aug 27, 2025

About Urteste

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 20
Stock Exchange Warsaw Stock Exchange
Ticker Symbol URT
Full Company Profile

Financial Performance

In 2024, Urteste's revenue was 1.80 million, an increase of 35.34% compared to the previous year's 1.33 million. Losses were -3.63 million, -35.00% less than in 2023.

Financial Statements

News

There is no news available yet.